2007_01 | Seventy-five percent of cancer drugs covered under Medicare Part D

NOW AVAILABLE
The next generation in online publishing...

Requires
Flash Player 9
Version Test
Download Flash

Sign up to read the digital versions of Managed Care, P&T, and Biotechnology Healthcare. These digital editions are free, searchable, and can be downloaded and read offline. To read a sample of the digital version of Managed Care, follow this link:

Sample digital edition

Register for a free digital subscription

Archive issues of Managed Care:

Supplement to Managed Care:

Tumor Necrosis Factor (TNF) Inhibitors
Free download

The Formulary Files

Seventy-five percent of cancer drugs covered under Medicare Part D

Seventy-five percent of cancer drugs are covered by Medicare Part D plans, with regional MA-PDPs (Medicare Advantage prescription drug plans) covering 85 percent.

Researchers at Avalere Health stratified the universe of cancer drugs covered by each Part D plan by contract type (local MA-PDP, regional MA-PDP, and stand-alone PDP). Prior authorization is the most common cost-limiting tool applied to brand-name cancer drugs, and PDPs and local MA-PDPs use prior authorization more frequently than regional MA-PDDs do. "Plans' use of policies such as prior authorization must be carefully monitored to ensure that cancer patients receive timely and appropriate treatment," says Jennifer Bowman, director and lead researcher of the study.

MANAGED CARE January 2007. ©MediMedia USA

The Formulary Files

Seventy-five percent of cancer drugs covered under Medicare Part D

Cancer drug coverage by Medicare Part D plan types